Business Context and Reporting Period
This Form 8-K Current Report, dated July 27, 2018, is filed by BeiGene, Ltd. (not Beone Medicines Ltd.), a Cayman Islands corporation. The report details the entry into a material definitive agreement regarding a proposed underwritten global offering of ordinary shares and the company's application to list on The Stock Exchange of Hong Kong Limited (SEHK).
Key Financial Metrics and Offering Terms
- Offering Size: 65,600,000 ordinary shares (par value $0.0001).
- Offering Structure:
- Hong Kong Offering: 5,904,000 shares (9% of total).
- Global Offering: 59,696,000 shares (91% of total).
- Over-Allotment Option: Joint global coordinators granted a 30-day option to purchase up to 9,840,000 additional shares.
- Expected Price Range: HK$94.40 to HK$111.60 per share (approximately US$12.03 to US$14.22 per share based on an exchange rate of HK$7.8491 to US$1.00).
- Expected Closing Date: August 8, 2018, subject to customary conditions.
- Listing Status: American Depositary Shares (ADSs) currently listed on NASDAQ (symbol: BGNE); ordinary shares to be listed on SEHK (stock code: 06160) following the offering.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics. Those figures are referenced as being available in the Company's Form 10-K and 10-Q filings.
Material Changes and Agreements
On July 27, 2018, the Company entered into a Hong Kong Underwriting Agreement with Morgan Stanley Asia Limited, Goldman Sachs (Asia) L.L.C., Credit Suisse (Hong Kong) Limited, CLSA Limited, China International Corporation Hong Kong Securities Limited, Deutsche Bank AG, Hong Kong Branch, UBS AG Hong Kong Branch, and China Renaissance Securities (Hong Kong) Limited. This agreement facilitates the Hong Kong portion of the dual-listing strategy.
Outlook, Risks, and Contingencies
The completion of the Offering is subject to market conditions and customary closing conditions. There is no assurance that the Offering will be completed, or as to the actual size or terms if completed. Key risks identified include:
- Possibility that pricing will not occur or closing conditions will not be met.
- Adverse market conditions.
- Offering expenses exceeding planned amounts.
- Failure of the Company or underwriters to perform obligations under the Underwriting Agreement.
The filing contains forward-looking statements regarding expectations for pricing and completion, which involve uncertainties that could cause actual results to differ materially.
Investor Verification Checklist
- Verify the final offering price and total shares sold once the Offering closes.
- Confirm the successful listing of ordinary shares on the SEHK under stock code 06160.
- Review the Company's Form 10-K (year ended Dec 31, 2017) and Form 10-Q (quarter ended March 31, 2018) for historical financial performance and liquidity data not included in this 8-K.
- Monitor for any updates regarding the exercise of the 30-day over-allotment option.
- Check for any changes in the exchange rate used for the US dollar conversion of the offering price.